Cas No.: | 705260-08-8 |
Chemical Name: | Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate sulfate |
Synonyms: | SCH530348, SCH 530348, SCH-530348, Vorapaxar sulfate, Vorapaxar |
SMILES: | C(OCC)(=O)N[C@H]1CC[C@]([H])2[C@]([H])(C1)C[C@@]([H])1C(=O)O[C@@H](C)[C@]1([H])[C@@H]2/C=C/C1=NC=C(C2=CC=CC(F)=C2)C=C1.S(O)(O)(=O)=O |
Formula: | C29H35FN2O8S |
M.Wt: | 590.6634 |
Sotrage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Description: | Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner[1]. |
In Vitro: | Vorapaxar sulfate (SCH 530348 sulfate) shows potent inhibition of thrombin-induced platelet aggregation with an IC50 of 47 nM and haTRAP-induced platelet aggregation with an IC50 of 25 nM. Vorapaxar sulfate (SCH 530348 sulfate) inhibits thrombininduced calcium transient in human coronary artery smooth muscle cells (HCASMC) with a Ki of 1.1 nM. It also inhibits thrombin-stimulated thymidine incorporation in HCASMC with a Ki of 13 nM[1]. |